Thomas Shrader, an analyst from BTIG, maintained the Buy rating on AC Immune SA. The associated price target is $8.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Thomas Shrader has given his Buy rating due to a combination of factors related to AC Immune’s advancing neurology pipeline and upcoming catalysts. He highlights the imminent ACI-24 Alzheimer’s vaccine plaque‑removal data as a potential game‑changer, especially if it shows strong amyloid reduction with a clean safety profile in high‑risk, early‑stage patients, and notes that prior immunogenicity results already support meaningful activity.
He also points to encouraging Parkinson’s disease data showing biologically coherent effects on alpha‑synuclein, neuronal injury markers, and motor scores, alongside the emerging NLRP3 inhibitor program, whose success could justify a valuation several times the current market cap. In addition, he underscores the de‑risked financial position, with cash expected to fund operations into 3Q27, and the upcoming tau small‑molecule program as further upside, all of which support a favorable risk‑reward profile at current levels.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $12.00 price target.